Abstract
We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
| Original language | English |
|---|---|
| Pages (from-to) | 1058-1060 |
| Number of pages | 3 |
| Journal | Pediatric Blood and Cancer |
| Volume | 62 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 2015 Jun 1 |
| Externally published | Yes |
Fingerprint
Keywords
- Genomic PCR
- MRD
- PDGFRB fusion
- Ph-like ALL
- TKI
ASJC Scopus subject areas
- Oncology
- Pediatrics, Perinatology, and Child Health
- Hematology
- Medicine(all)
Cite this
TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation. / Kobayashi, Kenichiro; Miyagawa, Naoyuki; Mitsui, Kazumasa; Matsuoka, Masaki; Kojima, Yasuko; Takahashi, Hiroyuki; Ootsubo, Kaori; Nagai, Junichi; Ueno, Hitomi; Ishibashi, Takeshi; Sultana, Sara; Okada, Yoko; Akimoto, Shingo; Okita, Hajime; Matsumoto, Kimikazu; Goto, Hiroaki; Kiyokawa, Nobutaka; Ohara, Akira.
In: Pediatric Blood and Cancer, Vol. 62, No. 6, 01.06.2015, p. 1058-1060.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - TKI dasatinib monotherapy for a patient with Ph-like ALL bearing ATF7IP/PDGFRB translocation
AU - Kobayashi, Kenichiro
AU - Miyagawa, Naoyuki
AU - Mitsui, Kazumasa
AU - Matsuoka, Masaki
AU - Kojima, Yasuko
AU - Takahashi, Hiroyuki
AU - Ootsubo, Kaori
AU - Nagai, Junichi
AU - Ueno, Hitomi
AU - Ishibashi, Takeshi
AU - Sultana, Sara
AU - Okada, Yoko
AU - Akimoto, Shingo
AU - Okita, Hajime
AU - Matsumoto, Kimikazu
AU - Goto, Hiroaki
AU - Kiyokawa, Nobutaka
AU - Ohara, Akira
PY - 2015/6/1
Y1 - 2015/6/1
N2 - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
AB - We report a 10-year-old male with relapsing Ph-like acute lymphoblastic leukemia (ALL) bearing ATF7IP/PDGFRB translocation. He was refractory to conventional therapy, and was finally treated with single-agent second-generation TKI dasatinib. The therapeutic response was prompt, with the disappearance of minimum residual disease (MRD) based on genomic PCR analysis within 3 months, and he has maintained complete molecular remission for 12 months. This case report describes an early-phase response to TKI monotherapy on Ph-like ALL, and technical tips for MRD monitoring on long-term follow-up.
KW - Genomic PCR
KW - MRD
KW - PDGFRB fusion
KW - Ph-like ALL
KW - TKI
UR - http://www.scopus.com/inward/record.url?scp=84927911280&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927911280&partnerID=8YFLogxK
U2 - 10.1002/pbc.25327
DO - 10.1002/pbc.25327
M3 - Article
C2 - 25400122
AN - SCOPUS:84927911280
VL - 62
SP - 1058
EP - 1060
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
SN - 1545-5009
IS - 6
ER -